Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
Status:
Active, not recruiting
Trial end date:
2024-07-25
Target enrollment:
Participant gender:
Summary
This research study is studying a chemotherapy as a possible treatment for Meningiomas
(recurrent).
The study intervention involved in this study is:
--AZD2014 (vistusertib)